Prof. Zhichao Wang and Prof. Yemima Berman address key challenges in NF1-PN treatment! скачать в хорошем качестве

Prof. Zhichao Wang and Prof. Yemima Berman address key challenges in NF1-PN treatment!

These breakthroughs and future directions are critical → The treatment dilemma for patients with NF1-PN has finally found new answers! Two leading authorities from China and Australia—Prof. Zhichao Wang from Shanghai Ninth People’s Hospital and Prof. Yemima Berman from Royal North Shore Hospital, Australia—engage in an in-depth dialogue packed with valuable insights. Prof. Zhichao Wang stated frankly: “In the past, when facing patients, the only options were surgery or watchful waiting. The emergence of MEK inhibitors has provided a crucial therapeutic weapon for clinical practice. Current retrospective studies in China have demonstrated differences in disease characteristics between Asian and Western populations. Clinical practice has also revealed the strong heterogeneity of NF1-PN, with significant variability in patient phenotypes. Individualized and precise treatment will be a key direction for future exploration.” Prof. Yemima Berman, with over 20 years of experience in NF1 research, pointed out: “MEK inhibitors represent a transformative breakthrough, significantly improving patients’ quality of life and attracting greater multidisciplinary attention to this rare disease. However, many clinical questions remain unanswered, such as the optimal timing for initiating MEK inhibitors, treatment duration, and efficacy prediction. In the future, further efforts are needed to cure NF1 and to prevent malignant transformation into MPNST.” In terms of research, both experts agree that racial differences, gaps in multicenter data, and mechanisms of malignant transformation are key challenges that must be addressed in the future, and that international collaboration is essential. Click the video to unlock the clinical expertise and research roadmap shared by Chinese and international experts, and gain a clear understanding of the breakthroughs and future directions in NF1-PN treatment. #NF1 #Neurofibromatosis #MedicalFrontiers #ExpertDialogue #PrecisionMedicine